Biomedical subjects

J Epelbaum

Publications and source records attributed to J Epelbaum.

At least 91 records · Page 5Linked to original sources

PubMed1995

Differential expression of somatostatin receptors by quantitative PCR in the rat brain.

Five subtypes of somatostatin receptors (sst) have recently been cloned and reported to be expressed in rat brain. However, conventional mRNA measurement techniques do not allow to accurately compare the levels of expression of the 5 sst. Thus, we established a quantitative reverse transcriptase polymerase chain reaction method for the 5 sst. A cRNA internal standard was constructed by inserting in msst1 plasmid sequences corresponding to specific sense primers for amplification of each sst. Using a common reverse primer, a unique primer pair by receptor amplifies both wild type and standard RNAs with the same efficiency. The technique was validated by evaluating sst mRNAs in 3 brain structures in which different somatostatin receptor binding levels were previously reported. While the absolute level of expression is similar between regions, sst3 is the major subtype in cerebellum, sst1 predominates in spinal cord and sst4 and sst2 are equally expressed in the hypothalamus.

Animals↗

PubMed1994

Immunocytochemical and in vitro autoradiographic evidence for a direct somatostatinergic modulation of the enkephalinergic hypothalamoseptal tract of the guinea-pig.

The present study was undertaken to determine whether the enkephalinergic hypothalamoseptal tract originating in the magnocellular dorsal nucleus in the guinea-pig brain is under the influence of somatostatin. In the first step, double immunocytochemical labeling of enkephalinergic cells and somatostatinergic fibers was combined at the light and electron microscopic levels in the magnocellular dorsal nucleus. As a second step, an in vitro radioautography was used to determine whether somatostatin receptors are present in the same area. A close relationship between somatostatin nerve endings and enkephalin perikarya was observed at both the light and electron microscopic levels. Contracts were more numerous in the ventral part of the magnocellular dorsal nucleus. Whenever synaptic images were clearly observable, they appeared symmetrical. In the same area, a moderate concentration of G-protein-coupled somatostatin binding sites was also visualized. These results suggest that somatostatin has a regulator role on the enkephalinergic hypothalamoseptal tract, directly at the level of the magnocellular dorsal nucleus.

Afferent Pathways↗

PubMed1994

The age-related increase in galanin binding sites in the rat brain correlates with behavioral impairment.

The regional distribution of [125I]galanin specific binding sites was determined in young (three- to four-month-old), 14-15-month-old and aged (26-27-month-old) male Sprague-Dawley rats, previously tested for their performances in the Morris water-maze task, using the radioautographic method on brain sections. A significant increase in specific binding was observed in piriform and entorhinal cortex, ventral subiculum, and dorsal dentate gyrus in the aged rats, whereas no significant changes were observed in dorsal subiculum, amygdala, septal area and various subcortical structures. The area-specific regional increase in specific binding density in aged rats was significantly correlated with the impairment of the behavioral performance in the Morris water-maze task. The change in [125I]galanin specific binding was a result of an increase in the number of galanin binding sites, but not of an increase in affinity.

Aging↗

PubMed1994

Developmental patterns of somatostatin-receptors and somatostatin-immunoreactivity during early neurogenesis in the rat.

The temporal pattern of distribution of somatostatin receptor was investigated using the somatostatin analogue [125I]Tyr0-DTrp8-somatostatin14 as a ligand and compared with that of somatostatin immunoreactivity during early developmental stages in the spinal cord and the sensory derivatives in rat fetuses. Qualitative and quantitative analysis showed that somatostatin receptors were detected in a transient manner. In the neural tube, they were clearly associated with immature premigratory cells and with the developing white matter. During the time-period examined (from day 10.5 to 16.5), the disappearance of somatostatin receptors followed a ventro to dorsal gradient probably linked to the regression of the ventricular zone. In sensory derivatives, they were expressed in the forming ganglia and their central and peripheral nerves from embryonic day 12.5 to 16.5 inclusive, with a peak around day 14.5 and low levels observed at day 16.5. Competition experiments performed at embryonic day 14.5 demonstrated that somatostatin1-14, somatostatin1-28, and Octreotide displaced specific binding with nanomolar affinities while CGP 23996 was only active at micromalar doses. Such displacements are compatible with the SSTR2 and/or SSTR4 pharmacology. During the time period examined, some transient somatostatin immunoreactive cell bodies and fibers were detected in the neural tube and in the sensory derivatives. These results demonstrate the existence, in neuronal derivatives, of a complex temporal and anatomical pattern of expression of somatostatin receptors, from the SSTR2/SSTR4 subtype(s), and somatostatin immunoreactivity. It appears that the transient expression of somatostatin receptors and/or somatostatin immunoreactivity characterizes critical episodes in the development of a cohort of neurons; a fact that unequivocally reinforces the notion that somatostatin plays a fundamental role during neurogenesis in vertebrates.

Animals↗

PubMed1994

Decreased choline acetyltransferase activity in nerve growth factor-transgenic mice during brain development.

Activity of the synthetic enzyme for acetylcholine, choline acetyltransferase was investigated during development and in adult nerve growth factor-transgenic mice. A conspicuous reduction of choline acetyltransferase activity was observed in the anterior brain of nerve growth factor-transgenic embryos from embryonic days 13 to 16 (E13 to E16). Choline acetyltransferase activity levels subsequently resumed to normal levels, with the exception of a 15% increase in the adult hippocampus. Nerve growth factor contents followed a similar time-course and regional distribution in normal and nerve growth factor-transgenic animals and displayed significantly higher values from E14 to the early postnatal period. Nerve growth factor contents were normal in the adult brain. In vitro experiments confirmed the involvement of nerve growth factor in the decrease of choline acetyltransferase activity levels observed in transgenic neurons during development. These results suggest a role for nerve growth factor in the initial phase of the phenotypic differentiation of cholinergic neurons. They show that nerve growth factor may, under specific development conditions, lead to a paradoxical down-regulation of choline acetyltransferase activity.

Aging↗

PubMed1994

Somatostatin messenger RNA-containing neurons in Alzheimer's disease: an in situ hybridization study in hippocampus, parahippocampal cortex and frontal cortex.

The level of expression of somatostatin messenger RNA-containing neurons in human brain was visualized and quantified by in situ hybridization with a 35S-labelled oligonucleotide complementary to amino acids 96-111 of the preprosomatostatin complementary DNA sequence. The analysis was carried out in the frontal and parahippocampal cortices and hippocampus of six age- and post mortem delay-matched Alzheimer's disease and control brains. By northern blot analysis, in frontal cortex samples, 18S rRNA degradation was identical in control and Alzheimer brains and somatostatin messenger RNAs migrated as a single band of 1 kb. By in situ hybridization, specificity was demonstrated by abolition of the signal using either an excess of unlabelled antisense probe or using a labelled sense probe. Somatostatin messenger RNA-containing neurons displayed a similar regional and subregional distribution in control subjects and patients with Alzheimer's disease, being more abundant in the frontal cortex, followed by the hippocampus and the parahippocampal cortex. An overall reduction of labelled cell density was observed in patients with Alzheimer's disease (frontal cortex gray matter:--41%; white matter:--66%; hippocampus:--44%; parahippocampal cortex white matter:--40%). Due to a great variation between brains, this decrease only reached significance in the parahippocampal cortex (-59%, P < 0.05). A significantly lower level of expression of somatostatin messenger RNA per somatostatinergic cell was observed in the hippocampus of Alzheimer's disease patients (-47%, P < 0.05), but not in frontal cortex gray (-17%) and white (-36%) matter and parahippocampal cortex gray (-42%) and white (-29%) matter. These data are in accordance with the distribution of somatostatin cells as visualized by immunohistochemistry in human brain. They indicate that the ability of cortical cells to express somatostatin messenger RNA is partially preserved in Alzheimer disease brains and that the decrease in the amount of somatostatin messenger RNA per cell is restricted to the hippocampal formation.

Aged↗

PubMed1994

Growth hormone-releasing hormone, somatostatin, galanin and beta-endorphin afferents to the hypothalamic periventricular nucleus.

A combined retrograde tracing (wheat germ agglutinin-horseradish peroxidase-gold complex)-immunohistochemical technique was used to identify the origin of growth hormone-releasing hormone (GHRH)-immunoreactive (ir), beta-endorphin-ir, galanin (GAL)-ir and somatostatin (SRIH)-ir terminals in the hypothalamic periventricular nucleus, which contains all the hypophysiotrophic SRIH-ir neurons. Retrogradely labeled cells were mostly observed ipsilaterally in the arcuate, dorsomedial (DMH), suprachiasmatic nuclei and the parvocellular part of the paraventricular nucleus. They were less abundant in the ventromedial and periventricular nuclei and in the lateral hypothalamus. The proportion of retrogradely labeled GHRH cells was greater at the outer rim of the ventromedial nucleus (10%) than in the arcuate nucleus proper (3%). In the arcuate nucleus, 14% of the SRIH-ir cells projected to the periventricular nucleus. Of the GAL-ir cells in the arcuate and the DMH 10% were double-labeled. Scattered retrogradely labeled GAL-ir cells were observed in paraventricular and perifornical nuclei and in the lateral hypothalamus. Of the beta-Endorphin-ir cells in the ventral part of the arcuate nucleus 15% were retrogradely labeled. It is concluded that: (1) There is no major direct connection between the hypophysiotropic GHRH and SRIH neurons, respectively, located in the arcuate and periventricular nucleus. (2) GHRH projections to the periventricular nucleus arise mainly from cells located at the outer rim of the ventromedial nucleus. (3) Intrahypothalamic SRIH projections to the periventricular nucleus arise from arcuate SRIH neurons located along the wall of the third ventricle. (4) GAL neurons from the DMH and the arcuate nucleus innervate to the same extent the periventricular nucleus. (5) beta-Endorphin arcuate neurons strongly innervate the periventricular nucleus.

Animals↗

PubMed1994

Influence of region-specific alterations of neuropeptidase content on the catabolic fates of neuropeptides in Alzheimer's disease.

We established the cartography of 11 exo- and endopeptidases in the frontal and parietal cortices and in the cerebellum of brains of patients diagnosed with a senile dementia of the Alzheimer's type (SDAT). Comparison with those of four subjects who had died without known neurologic or psychiatric illness indicated that there existed a region-specific alteration of the peptidase contents in the disease. In the frontal area of SDAT brains, postproline dipeptidyl aminopeptidase and aminopeptidase M activities were significantly reduced. In the parietal cortex of SDAT brain, activities of three additional endopeptidases--angiotensin-converting enzyme, proline endopeptidase, and endopeptidase 24.15--were also drastically reduced. In contrast, the cerebellum displayed a set of proteolytic activities that remained unaffected in SDAT brain. The putative influence of the disease on the catabolic fates of neurotensin, neuropeptide Y, and somatostatin(1-14) was investigated. Neurotensin was catabolized at identical rates in the frontal and parietal cortices in nondemented and SDAT brains. In contrast, neuropeptide Y metabolism was slowed down in SDAT brains in the frontal but not in the parietal cortex. Finally, the degradation velocities of somatostatin(1-14) were lowered in both cortical areas of SDAT brains. It is interesting that, by means of specific peptidase inhibitors, we demonstrated that endopeptidase 24.15 participated in somatostatin(1-14) inactivation in the parietal but not in the frontal cortex. It is suggested that the lowering of the rate of somatostatin(1-14) inactivation in the parietal cortex of SDAT brains likely results from the depletion of endopeptidase 24.15 in this brain region.

Aged↗

PubMed1994

Alpha-1-noradrenergic inhibition of growth hormone secretion is mediated through the paraventricular hypothalamic nucleus in male rats.

In the present work we investigated a possible role of an alpha 1-noradrenergic (NA) pathway involving the hypothalamic paraventricular nucleus (PVN) in the central regulation of growth hormone (GH) release. A week after bilateral electrolytic lesions of the PVN, pulsatile GH-secretory patterns were monitored in unanesthetized, freely moving control or lesioned male rats. While the pulsatility of GH secretion was maintained, the amplitude of the pulses and the area under the curve during an 8-hour sampling period were twice as high in PVN-lesioned than in control rats. Trough levels of GH were similar in the two groups. Inactivation of PVN alpha 1-receptors by local infusion of an alpha 1-NA antagonist, prazosin (50 ng/rat), also induced an increase in GH release. In control animals, intravenous injection of the alpha 1-NA agonist methoxamine (0.02 mg/100 g body weight) elicited a decrease in GH release but was ineffective when administered to PVN-lesioned rats. These data show that alpha 1-NA receptors, mediating GH inhibition, are located in the PVN. In light of the analogous effects observed herein on PVN-lesioned animals and, previously, after locus coeruleus (LC) lesions it is suggested that GH inhibition by the LC is relayed by the PVN via a local alpha 1-receptor population.

Adrenergic alpha-Agonists↗

PubMed1994

Somatostatin analogs for the localization and preoperative treatment of an adrenocorticotropin-secreting bronchial carcinoid tumor.

The diagnosis of the ectopic ACTH syndrome often remains difficult. Although bilateral inferior petrosal sinus sampling has recently offered a new approach, it does not help to localize an occult nonpituitary tumor. We report the case of a 45-yr-old woman whose hypercortisolism highly suggested the ectopic ACTH syndrome: elevated urinary free cortisol (3234 nmol/day, normal 28-143) was not suppressed by the high-dose dexamethasone test (2789 nmol/day); increased plasma ACTH (21.8 pmol/L, normal 2-11.4) did not respond to the ovine CRH test (23.8 pmol/L); and pituitary magnetic resonance imaging was negative. The thorax computed tomographic scan showed a questionable 7-mm nodular lesion in the upper part of the left lung. Because a 3-day trial of octreotide administration (200 micrograms sc every 8 h) induced a dramatic clinical and biological response with a drop in urinary free cortisol from 1738 to 441 nmol/day we performed a scintigraphy with [111In]pentetreotide; it revealed a single-well limited area of abnormal uptake at the exact location of the suspected thoracic lesion. This nodule was removed surgically after preparation of the patient by a 1-month treatment with octreotide: the tumor proved to be a typical bronchial carcinoid, containing extremely high concentrations of immunoreactive ACTH (198 pmol/mg wet wt tissue) and POMC messenger RNA by Northern blot. The presence of somatostatin receptors in the tumor was confirmed by in vitro radioautography. After surgery plasma cortisol and ACTH were undetectable. Somatostatin radioanalog scintigraphy should be considered as a new investigative tool in patients with suspected ectopic ACTH syndrome.

ACTH Syndrome, Ectopic↗

PubMed1994

Presence of somatostatin receptors negatively coupled to adenylate cyclase in ectopic growth hormone-releasing hormone- and alpha-subunit-secreting tumors from acromegalic patients responsive to octreotide.

The functional study of SRIH receptors was performed in ectopic GHRH-secreting tumors from two patients with acromegaly; patient 1 presented with multiple endocrine neoplasia type 1 with GHRH- and insulin-secreting pancreatic tumors, and patient 2 presented with a multihormone-secreting carcinoid tumor (including GHRH and alpha-subunit secretion, as demonstrated by clinical and immunohistochemical studies). In both cases, plasma GH levels were responsive to octreotide. In patient 2, plasma GHRH and alpha-subunit levels were responsive to octreotide. In vitro perifusion studies of a tumor fragment from patient 1 also showed inhibition of GHRH secretion by SRIH. A high density of specific SRIH-binding sites was visualized by autoradiography in GHRH tumors from both patients. SRIH specific binding was much higher in the GHRH tumors (6.6-8.4 fmol/surface unit) than in the insulinoma (1.9 fmol/surface unit). The binding inhibition constant (IC50) was in the nanomolar range (0.9-3 nmol/L) in the GHRH tumors. SRIH-14 inhibited forskolin-stimulated adenylate cyclase in the GHRH tumors from both patients, but not in the insulinoma. The functional SRIH receptors negatively coupled to adenylate cyclase present in ectopic GHRH-secreting tumors mediate the inhibitory effect of octreotide on GHRH secretion and on previously underrecognized ectopic alpha-subunit secretion from carcinoid tumors.

Acromegaly↗

PubMed1994

The neurobiology of somatostatin.

This review summarizes the recent findings on the localization of somatostatin (SRIF)-related peptides in local circuit interneurons and long projection neurons. These differential locations are discussed in relation to the multiple roles of SRIF 14 and SRIF 28 in neuroendocrine and autonomic regulation. The coexistence of SRIF with other neuropeptides and neurotransmitters, including nitric oxide, is described. The pharmacological and functional properties of the recently cloned family of SRIF receptor subtypes are reviewed as well as their localization. Finally, the decrease in SRIF concentrations in the cerebrospinal fluid (CSF) and the central nervous system (CNS) commonly associated with Alzheimer's disease is critically evaluated.

Animals↗

PubMed1993

Age-related increase in galanin-binding sites in the rat brain: correlation with behavioral impairment.

The regional distribution of 125I-galanin specific binding sites was determined by radioautography on brain sections in young (3- to 4-month-old) and aged (26- to 27-month-old) male Sprague-Dawley rats, previously tested for their performances in the Morris water maze task. In aged rats, a significant increase in specific binding was observed in piriform, perirhinal and entorhinal cortex, the CA1 field of the ventral hippocampus, ventral subiculum, and dorsal dentate gyrus, whereas no significant change was observed in the ventral dentate gyrus, the dorsal subiculum, the CA3 field of the hippocampus, the amygdala or the septal area. The area-specific regional increase in specific binding density in aged rats was significantly correlated with the impairment of their behavioral performances in the Morris water maze task. The change in 125I-galanin specific binding in the aged rats was a result of an increase in the number of galanin-binding sites, without change in affinity.

Aging↗

PubMed1993

Short- and long-term effects of nucleus basalis magnocellularis lesions on cortical levels of somatostatin and its receptors in the rat.

Cognitive and histological alterations in human Alzheimer's disease (AD) are correlated with selective neuronal loss in nucleus basalis of Meynert. In search of an animal model of AD-linked neurochemical deficits, we examined the effects of short- (2 weeks) and long- (3 and 6 months) term lesions of the nucleus basalis magnocellularis (NBM) on somatostatinergic parameters in rat forebrain. NBM lesions were performed by unilateral injection of ibotenic acid into the NBM. Cortical choline-acetyl transferase (ChAT) activity and acetylcholinesterase staining in the NBM remained significantly decreased ipsi- as compared to contralaterally up to 6 months after the placement of the lesion. Somatostatin (SRIF) content was increased by 120% in the ipsilateral frontal cortex 6 months post-lesion but not at shorter time intervals. Levels of neuropeptide Y (which is extensively co-localized with SRIF in the forebrain) were not significantly altered after unilateral NBM lesions at any time point. A 30% decrease in SRIF binding capacity as well as a marked reduction of SRIF inhibition of adenylate cyclase, indicative of a loss of functional SRIF receptors, was observed in ipsilateral versus contralateral frontal cortex on brain tissue homogenates after short-term unilateral NBM lesion. By film radioautography, the loss in SRIF binding sites was localized to both superficial and deep layers of the frontal cortex. This loss persisted up to 3 months but was no longer apparent after 6 months due to a decrease in SRIF binding capacity on the contralateral side.

Adenylyl Cyclase Inhibitors↗

PubMed1993

ATP-modulated K+ channels sensitive to antidiabetic sulfonylureas are present in adenohypophysis and are involved in growth hormone release.

The adenohypophysis contains high-affinity binding sites for antidiabetic sulfonylureas that are specific blockers of ATP-sensitive K+ channels. The binding protein has a M(r) of 145,000 +/- 5000. The presence of ATP-sensitive K+ channels (26 pS) has been demonstrated by electrophysiological techniques. Intracellular perfusion of adenohypophysis cells with an ATP-free medium to activate ATP-sensitive K+ channels induces a large hyperpolarization (approximately 30 mV) that is antagonized by antidiabetic sulfonylureas. Diazoxide opens ATP-sensitive K+ channels in adenohypophysis cells as it does in pancreatic beta cells and also induces a hyperpolarization (approximately 30 mV) that is also suppressed by antidiabetic sulfonylureas. As in pancreatic beta cells, glucose and antidiabetic sulfonylureas depolarize the adenohypophysis cells and thereby indirectly increase Ca2+ influx through L-type Ca2+ channels. The K+ channel opener diazoxide has an opposite effect. Opening ATP-sensitive K+ channels inhibits growth hormone secretion and this inhibition is eliminated by antidiabetic sulfonylureas.

Adenosine Diphosphate↗

PubMed1993

125I-somatostatin-labeled cells in the anterior arcuate nucleus mediate somatostatin effects on growth hormone but not prolactin secretion.

The regional brain distribution of 125I-somatostatin (SRIH) binding sites was determined by quantitative radioautography in neonatally monosodium glutamate (MSG) treated adult male rats, a procedure which selectively destroys most neurons of the arcuate nucleus. Neonatal MSG treatment did not modify the extrahypothalamic distribution of 125I-SRIH-binding sites. In contrast, the number of 125I-SRIH-labeled cells in the ventrolateral part of the arcuate nucleus was strongly reduced in MSG-treated animals. The effect was selective for the anterior part of the arcuate nucleus and was not found in its posterior part or in the cells located more dorsally, beneath the ependymal zone of the periventricular nucleus. Intracerebroventricular SRIH injections, which increased growth hormone levels in control rats, were totally ineffective in MSG-treated animals. In contrast, the prolactin levels were equally stimulated by intracerebroventricular injections in control and MSG-treated animals. These results demonstrate that extrahypothalamic SRIH-binding sites are not located on neurons originating in the anterior arcuate nucleus neurons. In addition, 125I-SRIH-labeled cells in the ventrolateral part of the arcuate nucleus are necessary for the paradoxical stimulation of growth hormone secretion induced by intracerebroventricular SRIH injection, but do not seem to be essential for the increased prolactin secretion observed under these conditions.

Animals↗

PubMed1993

Chronic growth hormone (GH) hypersecretion induces reciprocal and reversible changes in mRNA levels from hypothalamic GH-releasing hormone and somatostatin neurons in the rat.

Effects of growth hormone (GH) hypersecretion on somatostatin-(SRIH) and GH-releasing hormone (GHRH) were studied by in situ hybridization and receptor autoradiography in rats bearing a GH-secreting tumor. 6 and 18 wk after tumor induction, animals displayed a sharp increase in body weight and GH plasma levels; pituitary GH content was reduced by 47 and 55%, while that of prolactin and thyrotropin was unchanged. At 18 wk, hypothalamic GHRH and SRIH levels had fallen by 84 and 52%, respectively. In parallel, the density of GHRH mRNA per arcuate neuron was reduced by 52 and 50% at 6 and 18 wk, while SRIH mRNA levels increased by 71 and 83% in the periventricular nucleus (with no alteration in the hilus of the dentate gyrus). The numbers of GHRH- and SRIH-synthetizing neurons in the hypothalamus were not altered in GH-hypersecreting rats. Resection of the tumor restored hypothalamic GHRH and SRIH mRNAs to control levels. GH hypersecretion did not modify 125I-SRIH binding sites on GHRH neurons. Thus, chronic GH hypersecretion affects the expression of the genes encoding for GHRH and SRIH. The effect is long lasting, not desensitizable and reversible.

Animals↗

PubMed1993

Somatostatin receptors, adenylate cyclase activity, and growth hormone (GH) response to octreotide in GH-secreting adenomas.

To determine the cellular mechanism(s) of the variability in GH responsiveness to octreotide in acromegaly, somatostatin (SRIH) receptor status was studied in 37 GH-secreting adenomas. SRIH receptor binding was always present in all GH-secreting adenomas either in membrane preparations (Exp A; n = 17) or by quantitative autoradiography (Exp B; n = 20). In membranes, maximal binding capacities ranged from 83-2331 fmol/mg protein; affinity was in the nanomolar range (Kd, 1.3 +/- 0.2 nmol/L). By quantitative autoradiography, SRIH-14 and octreotide were equally active in displacing [125I]SRIH binding in tumors (Spearman correlation rho = 0.92). IC50 values ranged from 3-22 nmol/L (mean +/- SE, 8.0 +/- 1.3 nmol/L). In Exp A, basal adenylate cyclase (AC) activity was high in 7 tumors (841 +/- 306 pmol/L cAMP x 30 min/mg protein) compared to that in the other 10 (252 +/- 92 pmol/L cAMP x 30 min/mg protein). In these 7 tumors, GH-releasing hormone (0.1 mumol/L) stimulation of AC was lower (53 +/- 11% vs. 297 +/- 48%), whereas SRIH (1 mumol/L) inhibition was higher (52 +/- 5% vs. 34 +/- 5%). Similar results were obtained with Exp B tumors. In both experiments, no correlation was apparent between SRIH-binding capacity and inhibition of AC. In Exp B, a variable decrease in mean plasma GH levels was observed (> or = 80% in 5 patients, between 50-80% in 8 patients, and < or = 50% in 5 patients) after a single sc injection of octreotide (100 micrograms). A modest correlation was found between the GH response to octreotide and SRIH-binding capacity (rho = 0.48) or SRIH inhibition of AC (rho = 0.61). The IC50 values to displace SRIH binding were lower in poorly responsive patients than in highly responsive ones (IC50, 4.6 +/- 1.9 and 13.9 +/- 2.7 nmol/L, respectively). These data indicate that an absence of SRIH receptors cannot account for the weak response to SRIH therapy in 20-30% of acromegalic patients. Alternatively, the weak correlation between either SRIH binding or SRIH inhibition of AC with octreotide inhibition of plasma GH levels might reflect the heterogeneity of SRIH receptor subtypes in GH-secreting adenomas.

Adenoma↗